Follow us on Twitter
twitter icon@FreshPatents


Immune Response patents

      

This page is updated frequently with new Immune Response-related patent applications.




 Humanized monoclonal antibodies and methodsof use patent thumbnailHumanized monoclonal antibodies and methodsof use
The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene vh1-69. This antibody is derived from mab g6 and recognizes the same epitope.
Dana-farber Cancer Institute, Inc.


 Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function patent thumbnailMonoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function
Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital


 Compositions and methods for anti-lyst immunomodulation patent thumbnailCompositions and methods for anti-lyst immunomodulation
Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the lyst protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage.
Research Institute At Nationwide Children's Hospital


 Particulate vaccine formulations for inducing innate and adaptive immunity patent thumbnailParticulate vaccine formulations for inducing innate and adaptive immunity
Disclosed are compositions, kits, and methods for inducing an immune response against an infection or a disease. The compositions typically include biodegradable particles having an average effective diameter that such that the biodegradable particles are phagocytosed by antigen presenting cells when the biodegradable particles are administered to a subject in need thereof.
Auburn University


 A composition comprising ex-vivo generated dendritic cells patent thumbnailA composition comprising ex-vivo generated dendritic cells
The present invention relates to a composition comprising ex-vivo generated antigen-loaded dendritic cells in combination with β-glucan and hyaluronic acid or pharmaceutically acceptable derivatives thereof and methods of preparing and delivering the same. The present composition of the present invention enhances antigen-specific t cell response against cancer cells.

 Novel immunogenic composition patent thumbnailNovel immunogenic composition
Recombinant chimeric viruses based on ndv lasota strain and containing either iltv gb or gd are produced. Administration of the chimeric viruses to chickens induces an immune response in the animal against both ndv and iltv.
The United States Of America, As Represented By The Secretary Of Agriculture


 Multivalent vlp conjugates patent thumbnailMultivalent vlp conjugates
The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc


 Antigen specific multi epitope vaccines patent thumbnailAntigen specific multi epitope vaccines
The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple mhc class i and class ii epitopes which are highly abundant in the population.
Vaxil Biotherapeutics Ltd.


 Tumor vaccination involving a humoral immune response against self-proteins patent thumbnailTumor vaccination involving a humoral immune response against self-proteins
The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis b virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject..
Biontech Ag


 Prenatal therapy to induce immune tolerance patent thumbnailPrenatal therapy to induce immune tolerance
Constructs and methods for inducing immune tolerance during gestation, e.g. In utero, are provided.
Inserm (institut National De La Santé Et De La Recherche Médicale)


Enhancing serological assays via fusion proteins

A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
Cornell University

Attenuated viruses useful for vaccines

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject.
The Research Foundation For The State University Of New York

Method for in situ inhibition of regulatory t cells

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg).
Cellectis

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Chimeric vaccines

The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein.
The Johns Hopkins University

Vesicular stomatitis virus for prime boost vaccine

The present invention relates to vesicular stomatitis virus (vsv) matrix (m) protein mutants. One mutant m protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51.
The University Of Western Ontario

Methods and compositions for producing an adenovirus vector for use with multiple vaccinations

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Adenoviral vector vaccine

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of cd40 ligand, which is missing all or substantially all of the transmembrane domain rendering cd40l secretable.
Vaxum, Llc

Method and composition for modulating immune response

Provided is a method for modulating an immune response which is not derived from alphavirus infection comprising administering to a subject in need thereof an effective amount of a composition comprising an alphavirus virus like particle.. .
Vlp Therapeutics, Llc

Methods of modulating an immune response

The present invention relates to methods of modulating an immune response in a subject by using a binding protein (e.g., an antibody or an antigen-binding portion of an antibody) to mask or alter an epitope on an antigen that is administered to the subject. Such methods are useful for inducing an immune response (e.g., production of an antibody) in the subject to a non-immunodominant epitope on the antigen.
Cangene Corporation

Process for preparing an attenuated tetravalent dengue vaccine

The present invention refers to a process for preparing an attenuated tetravalent dengue vaccine and its product. The present invention also refers to a process for preparing a tetravalent dengue vaccine for administration to a subject, to a method for inducing an immune response to virus dengue serotype 1, 2, 3 and 4 in a patient and to a tetravalent dengue vaccine kit..
Fundacao Butantan

Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

The present invention generally provides methods and compositions for eliciting an immune response against neisseria spp. Bacteria in a subject, particularly against a neisseria meningitidis serogroup b strain..
Children's Hospital & Research Center Oakland

Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the ras protein, but has one to three point mutations thereof.
Targovax Asa

Sequential administration of a replication defective adenovirus vector in vaccination protocols

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Rna viruses for immunovirotherapy

The present invention relates to a recombinant virus of the family paramyxoviridae, comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer..
Ruprecht-karls-universitat Heidelberg

Compositions and methods for intradermal vaccine delivery

The present invention relates, generally, to compositions comprising at least one antigen encapsulated within at least one fibrous polymer matrix and their use in intradermal vaccine delivery. It has been discovered that the intradermal delivery of antigens into the antigenpresenting cell-rich layers of the skin requires less antigen than traditional vaccine delivery methods and is still capable of eliciting an immune response comparable to that observed with traditional vaccine delivery methods..
The Research Foundation For The State University Of New York

Method of activating immune response in plants

A method of enhancing plant immunity is provided. The method comprises the step of administering to a plant a small molecule that binds to npr1, or a functionally equivalent homolog thereof, that disrupts the interaction between n-terminal btb/poz domain and the c-terminal transactivation domain of npr1.

Plant pattern recognition receptor and chimeras thereof for use against bacterial infections

The present invention relates to the finding that an until now orphan protein named receptor-like protein 1 (rlp1) in plants mediates an immune response to bacterial infections. Specifically, the invention relates to rlp1, now named receptor of enigmatic microbe-associated molecular pattern (mamp) of xanthomonas (remax), in arabidopsis thaliana remax was found to recognise the presence of xanthomonas and to initiate an immune signalling that eventually yields into a typical plant immune responses to bacterial infections.
Eberhard Karls Universitaet Tuebingen

Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways

Described herein are novel compositions comprising il-27 or nfil-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..
The Brigham And Women's Hospital, Inc.

Virus like vesicles (vlvs) based vaccines to prevent or treat chronic hepatitis b virus (hbv) infection

The present invention relates to the discovery of compositions and methods for therapeutic immunization for treatment of chronic hepatitis b. Methods of the invention include a method generating an evolved high titer hybrid-hepatitis b virus (hbv) vector, methods of treating and/or preventing hbv, and methods of inducing a memory t and b cell immune response against hbv infection in a subject administered the vlv composition produced thereby.
Yale University

Adenoviral vector-based vaccine against enterovirus infection

The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a pi protein and a 3 cd protease of an enterovirus.
Lu-hai Wang

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination

Disclosed are methods whereby an effective amount of a hdac6 inhibitor is used to activate a subjects t-cell response to tumor or tumor vaccine. Methods of using hdac6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed..
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Biomarkers for prostate cancer and methods for their detection

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.. .
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Evolution of high-titer virus-like vesicles for vaccine applications

The present invention relates to the discovery of a high titer hybrid-virus vector that gives rise to high titer virus like vesicles (vlvs) that can be used as a vaccine. The invention includes compositions and methods of generating an evolved hybrid-virus vector vaccine and selecting high titer vlvs, methods of treating and/or preventing or immunizing against, a specific disease or disorder, and methods of inducing a memory t cell and b cell immune response in a subject administered the vlv composition produced thereby.
Yale University

Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof

The present invention provides antibodies that bind to prostate-specific membrane antigen (psma), bispecific antibodies that bind to psma and cd3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human psma with high affinity and bind cd3 to induce human t cell proliferation.
Regeneron Pharmaceuticals, Inc.

Method of providing monoclonal auto-antibodies with desired specificity

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
Immunoqure Ag

Factor viii b cell epitope variants having reduced immunogenicity

Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
Bloodworks

Plasmodium falciparum antigens

The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against plasmodium falciparum. The inventive antigens were identified by their association with sterile immunity against malaria..
United States Of America As Represented By The Secretary Of The Navy

Compositions, methods and uses for dengue virus serotype-4 constructs

Embodiments herein report compositions, methods and uses for dengue-4 (denv-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, denv-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject.
Takeda Vaccines, Inc.

Vaccine candidates against johne's disease

A composition and method for immunizing a mammal infected with mycobacterium are disclosed. The genes gcpe, psta, kdpc, papa2, impa, umaa1, fabg2_2, aceab, mbth2, ipqp, map0834c, cspb, lipn, and map1634 of m.
Wisconsin Alumni Research Foundation

Vaccines based on hepatitis b core antigens

The invention provides a protein comprising hepatitis b core antigen (hbcag) with a sugar attached to an e1 loop. The protein may comprise a first and a second copy of hbcag in tandem, wherein one or both copies of hbcag has a sugar attached to the e1 loop.
Iqur Limited

Method to enhance an immune response of nucleic acid vaccination

A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein..
Lipoxen Technologies Limited

Chimpanzee adenoviral vector-based filovirus vaccines

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of ebolavirus (ebov) or marburg virus (marv)..
Glaxosmithkline Biologicals Sa

Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor.
Oncomed Pharmaceuticals

Human sperm fibrous sheath (fs) proteins: new target antigens for use in therapeutic cancer vaccines and diagnostic screening and methods of using same

Cancer vaccines were demonstrated to be promising strategies for cancer treatment; however these strategies are limited by the paucity of target antigens that provoke an effective immune response. The inventors of the present patent application propose that sperm fibrous sheet proteins constitute a new class of potential antigens for use in the development of effective, durable cancer vaccines.
Kiromic, Llc

Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines

The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey

Bioactive conjugates for oligonucleotide delivery

Provided herein are self-delivering oligonucleotides that are characterized by efficient risc entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.. .
University Of Massachusetts

Smallpox vaccine for cancer treatment

Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response..
Stemimmune, Incorporated

Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Provided herein are recombinant modified vaccinia virus ankara (mva) strains as improved vaccines against infection with respiratory syncytial virus (rsv virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant mva vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an rsv membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an rsv nucleocapsid protein.
Bavarian Nordic A/s

Biodegradable nanocomplex

The present invention relates to a biodegradable nanocomplex. The biodegradable nanocomplex comprises a first electrically charged substance, a charge-redistribution substance, a second electrically charged substance and a carried substance, for holding the carried substance inside.
National Cheng Kung University

Chlamydia antigens and uses thereof

The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., t cell-mediated and/or b cell-mediated immune responses).
Genocea Biosciences, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.



Immune Response topics:
  • Immune Response
  • Antibodies
  • Polypeptide
  • Monoclonal
  • Monoclonal Antibody
  • Polymyxin B
  • Immunostimulator
  • Vaccination
  • Stimulator
  • Immunogenic
  • Nucleic Acid
  • Major Histocompatibility Complex
  • Histocompatibility
  • Vaccine Adjuvant
  • Compatibility


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immune Response for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Response with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.1508

    file did exist - 2853

    2 - 1 - 56